Splenic Marginal Zone B-Cell Lymphoma is an indication for drug development with over 30 pipeline drugs currently active. According to GlobalData, preregistered drugs for Splenic Marginal Zone B-Cell Lymphoma have a 66.67% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Splenic Marginal Zone B-Cell Lymphoma compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Splenic Marginal Zone B-Cell Lymphoma overview
Splenic marginal zone lymphoma (SMZL) is a rare type of B-cell lymphoma that affects the spleen, bone marrow, and sometimes the blood. It is a low-grade neoplasm that originates from the germinal centers of the splenic white pulp. The neoplastic cells are small lymphocytes and larger transformed lymphoblasts that invade the mantle and marginal zones of the spleen and erode its normal architecture. SMZL may be associated with hepatitis C virus infection in some cases. The diagnosis of SMZL requires the presence of splenomegaly and splenic histology. The bone marrow may show nodular infiltration by neoplastic cells with marginal zone differentiation. Peripheral blood may contain villous lymphocytes with plasmacytoid features. SMZL is an indolent disease that may not require immediate treatment unless symptoms or cytopenias are present. Rituximab-based therapies are effective in most patients, and novel agents are being investigated for relapsed or refractory cases.
For a complete picture of PTSR and LoA scores for drugs in Splenic Marginal Zone B-Cell Lymphoma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
